GlassScriptPhysician profile
Stephen D Summerow
NPI 1912039595
$222,270.58
in general payments reported to CMS, 2019-2025
23 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $6,770 · 2021: $22K · 2022: $50K · 2023: $19K · 2024: $37K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Honoraria: $27K · Travel and Lodging: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Food and Beverage: $9,951 · Consulting Fee: $4,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,062.50 |
| Honoraria | $27,100.00 |
| Travel and Lodging | $23,177.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,250.00 |
| Food and Beverage | $9,951.05 |
| Consulting Fee | $4,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $99,013.74 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $37,339.68 | 2024-2025 | Vevye |
| Abbvie INC. | $18,094.87 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $15,466.45 | 2019-2023 | |
| Alcon Vision LLC | $13,937.11 | 2019-2025 | Tryptyr, Precision7, Eysuvis |
| Shire North American Group INC | $13,045.77 | 2019 | |
| Allergan, INC. | $11,738.60 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $10,161.45 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $677.33 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $468.87 | 2022-2025 | Tyrvaya |
| Amgen INC. | $441.81 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $348.94 | 2023-2025 | Miebo, Scoutpro Osmolarity System, Vyzulta |
| Eyevance Pharmaceuticals LLC | $328.23 | 2019-2022 | |
| Dompe US, INC. | $308.67 | 2022-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $280.34 | 2021-2025 | Acuvue |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $204.91 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $198.04 | 2019-2021 | |
| Thea Pharma INC. | $78.97 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.96 | 2019-2020 | |
| Akorn Operating Company LLC | $30.11 | 2021 | |
| Ani Pharmaceuticals, INC. | $24.02 | 2025 | Purified Cortrophin Gel |
| Tearlab Corp | $23.74 | 2024 | Scoutpro Osmolarity System |
| Coopervision INC. | $15.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Summerow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.